| Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. | |
| | |
MedLine Citation:
|
PMID: 23299278 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this study was to retrospectively investigate clinical outcomes by relative dose and dose intensity of docetaxel (DOC) as chemotherapy for Japanese patients with castration-resistant prostate cancer (CRPC). METHODS: A total of 145 CRPC patients who received more than 4 courses of DOC chemotherapy at 14 hospitals between 2005 and 2011 were enrolled. Patients were divided into two groups-those receiving a higher or lower dose (mg/m(2)) or dose intensity (mg/m(2)/week). Differences between the groups regarding treatment outcomes and adverse events (AEs) were determined. Additionally, prognostic factors predictive of cancer-specific survival (CSS) in these patients were identified by both univariate and multivariate analysis. RESULTS: The total patient group underwent a mean of 11.2 ± 7.4 DOC cycles, and the mean CSS after therapy was 15.6 ± 10.1 months. The higher-dose group had a better prostate-specific antigen (PSA) response than the lower-dose group. However, there was no significant difference between the groups in prognosis after DOC chemotherapy. Leukopenia and neutropenia were observed more frequently in the higher-dose group. Serum biomarkers (including PSA, lactate dehydrogenase and alkaline phosphatase), hemoglobin levels and presence of pain at initiation of chemotherapy, as well as the PSA nadir level on first-line hormone therapy, all were significant predictors of CSS. CONCLUSIONS: In the Japanese population, relatively low-dose DOC chemotherapy had no deleterious effect on the CSS of CRPC patients, and a lower incidence of AEs occurred, in spite of a diminished PSA response compared with those receiving a higher dose. |
| | |
Authors:
|
Naoto Kamiya; Hiroyoshi Suzuki; Takeshi Ueda; Naohide Sato; Hiroomi Nakatsu; Kazuo Mikami; Nobuo Sato; Kazushi Nomura; Koichiro Akakura; Tatsuya Okano; Takemasa Ooki; Yukio Naya; Sho Ota; Motoyuki Masai; Tomohiko Ichikawa |
Related Documents
:
|
10773408 - Inhibition by methionine of pancreatic carcinogenesis in hamsters after initiation with... 18723908 - Efficacy of two dose regimes of intravenous immunoglobulin in rh hemolytic disease of n... 11992708 - Vaccination of donkeys against babesia equi using killed merozoite immunogen. 17943548 - The effect of resveratrol on prevention of the development of postoperative adhesions i... 22520338 - Efficacy of slow-release collar formulations of imidacloprid/flumethrin and deltamethri... 3965628 - A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the to... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: - ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan, naoto.kamiya@med.toho-u.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and correspondi...
Next Document: Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit fro...